Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to TNF Antagonists
OPEN Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 19 Sep 2016
BG Feagan, DT Rubin, S Danese, S Vermeire, B Abhyankar, S Sankoh, A James and M Smyth
The efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal antibody against the integrin α4β7, was demonstrated in multicenter, phase 3, randomized, placebo-controlled trials in patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease. We analyzed data from 1 of these trials to determine the effects of vedolizumab therapy in patients with UC, based on past exposure to anti-tumor necrosis factor (TNF) agents.
* Data courtesy of Altmetric.com